A unique target against the key neurodegenerative mechanisms : toward a disease modifying treatment
ENCEFA, biopharmaceutical company steeming from the French Brain and Spinal cord Institute (ICM), develops biologics acting through an unprecedented mechanism of action against neurodegeneration. Founded in 2016, ENCEFA is located at the Pitié Salpêtrière Hospital.
Chief executive officer, Laurence is an economist with more than 15 years of experience in consulting, management and SME development. She made the most of her skills in international companies such as DELOITTE and do not hesitate to follow numerous formations to still improve her skills !
Chief scientific officer, Damien holds a PhD in Cellular Neuroscience from the Brain and Spine Institute (ICM). Prior to join ENCEFA, Damien worked in a consulting firm specialized in life science, and then in another Biotechnology company as neuroscience project manager for experimental biology.
Chief technology officer, Serge is a biotech engineer. His 13 years of experience in molecule research in neuroscience firstly among Pitié Salpétrière laboratory, then ICM and then ENCEFA are key. He is at the origin of ENCEFA's discovery and has already contributed to 2 molecules in neuroscience that have been clinically tested.
Institut du Cerveau et de la Moelle Epinière – ICM is a research center of international dimension that gathers patients, doctors and researchers in order to speed up the discovery of innovative therapeutic medecines against affections of the nervous system.
ICM opens its doors to ENCEFA in order to share its platforms, equipment and ecosystem that are cutting edge of technology.
iPEPS incubator – accommodate ENCEFA in its premises
ENCEFA’s team has the support of international experts, clinical professionals specialized in ALS and PARKINSON, industrial experts with high responsibilities and successful startup managers.